Physician profile
Taylor Grimm
NPI 1841958659
$3,566.60
in general payments reported to CMS, 2019-2025
24 companies · $889 in 2025
The $889 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.03 · 2022: $755 · 2023: $802 · 2024: $1,051 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.57 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.51 | 2022-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $315.87 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $283.29 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $246.10 | 2022-2025 | Linzess |
| Madrigal Pharmaceuticals | $183.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $168.31 | 2022-2023 | |
| Pfizer INC. | $144.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.66 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $106.78 | 2022-2023 | Injectafer |
| Genzyme Corporation | $106.41 | 2023-2024 | |
| Qol Medical, LLC | $105.74 | 2023-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $105.12 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $80.35 | 2021-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $63.25 | 2024 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $52.03 | 2022-2025 | Tremfya |
| Celgene Corporation | $44.15 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $42.99 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $38.32 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $34.45 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $22.44 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.60 | 2024 | Cyltezo |
| Organon LLC | $18.83 | 2025 | Renflexis, Hadlima |
| Shield Therapeutics INC | $16.64 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.